Shanghai Henlius Biotech Anti-CD73 Antibody Patent US12606633B2

Tue, 21 Apr 2026 14:20:15 +0000
Intellectual Property

The USPTO granted Patent US12606633B2 to Shanghai Henlius Biotech, Inc. on April 21, 2026, covering anti-CD73 antibodies, variants, and antigen binding fragments that bind human CD73 with high affinity and suppress enzymatic activity. The patent includes 17 claims and covers isolated nucleic acid molecules, expression vectors, host cells, and related pharmaceutical compositions for treating subjects.